Clinical Trial Update: Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008) [Phase 2]

View source ↗

Summary

Phase 2 trial MK-8189-008 evaluates the efficacy and safety of MK-8189 in participants with an acute episode of schizophrenia. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• MK-8189

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED | Results posted: 2025-08-22